ESMO 2024 – Bristol heads for phase 3 in small-cell
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
World Lung 2024 – Lilly eyes a first-line KRAS triplet
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Just how independent is Genentech?
Questions continue to swirl as the unit mulls another oncology makeover.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
